Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBITDA Margin (2024 - 2025)

Monte Rosa Therapeutics' EBITDA Margin history spans 2 years, with the latest figure at 1679.79% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 170024.0% year-over-year to 1679.79%; the TTM value through Dec 2025 reached 31.61%, up 6536.0%, while the annual FY2025 figure was 31.61%, 6536.0% up from the prior year.
  • EBITDA Margin reached 1679.79% in Q4 2025 per GLUE's latest filing, down from 211.11% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 55.24% in Q1 2025 to a low of 3001.6% in Q1 2024.